Spinal cord stimulation - Neuromodulation.co

What Is SCS?

What Is SCS? Spinal cord stimulation (SCS) is an implantable neuromodulation therapy that delivers controlled electrical pulses to the dorsal aspect of the spinal cord to reduce chronic, refractory pain. The treatment involves placing one or more electrode leads in the epidural space and connecting them to an implantable pulse generator (IPG), which produces programmable electrical waveforms. By modulating afferent neural activity within dorsal column and dorsal horn pathways, SCS aims to decrease the transmission or perception of nociceptive signals before they reach supraspinal centers. What Is SCS? This therapy is designed to alleviate pain through targeted electrical stimulation. Historically, SCS was inspired by the gate control theory of pain, proposed by Melzack and Wall in 1965, which suggested that activating large-diameter Aβ fibers could inhibit nociceptive input. The first human implantation was performed by Shealy in 1967, marking the beginning of targeted bioelectronic pain therapies. Traditional “tonic” SCS relied on generating paresthesias overlapping the painful region, but rapid technological development has expanded the therapeutic landscape. Modern systems now include paresthesia-free paradigms such as high-frequency stimulation, burst stimulation, and closed-loop systems that use evoked compound action potentials to automatically adjust stimulation intensity in real time. What Is SCS? It provides a means to manage pain where traditional methods have failed. Clinically, SCS is used for chronic neuropathic and mixed pain conditions that are refractory to conservative management, including failed back surgery syndrome, complex regional pain syndrome, painful diabetic neuropathy, and certain forms of visceral or ischemic pain. Across decades of clinical use, SCS has demonstrated meaningful reductions in pain, improvements in function and quality of life, and decreased reliance on analgesic medications for many carefully selected patients. Ongoing innovations in targets, waveform design, and adaptive stimulation aim to further refine its efficacy and broaden its applications. What Is SCS’s impact on daily life? Patients often report improved quality of life. What Is SCS in terms of patient outcomes? Many experience significant relief from chronic pain. History of SCS Understanding What Is SCS What Is SCS? It has evolved significantly since its inception in the late 20th century. What Is SCS’s historical context? It was first developed based on the gate control theory. The development of spinal cord stimulation (SCS) emerged directly from the gate control theory of pain proposed by Melzack and Wall in 1965, which suggested that activation of large-diameter dorsal column fibers could inhibit nociceptive transmission. Building on this concept, Norman Shealy performed the first dorsal column stimulation in 1967, demonstrating that epidural electrical stimulation could provide meaningful analgesia in patients with refractory cancer pain (Shealy 1967). Early systems were rudimentary, involving subdural electrodes and external power sources, but they established the foundational principle that pain could be modulated through targeted electrical input. During the 1970s and 1980s, technological refinement accelerated as fully implantable pulse generators and percutaneous epidural leads were introduced, significantly reducing procedural morbidity and expanding clinical adoption. By the 1990s, multichannel leads, improved battery systems, and programmable stimulation parameters allowed more individualized therapy, while computational models enabled better prediction of dorsal column recruitment (North 1991; Holsheimer 1998). What Is SCS’s technological advancement? The introduction of programmable devices has revolutionized treatment. The 2010s marked a major paradigm shift with the emergence of paresthesia-free stimulation, including high-frequency (10 kHz) therapy and burst stimulation, providing analgesia without sensory perception (De Ridder 2013). Most recently, closed-loop SCS using evoked compound action potential feedback has enabled real-time adjustment of stimulation intensity, offering more stable analgesia across posture and activity changes (Mekhail 2020). What Is SCS now? It uses advanced systems for real-time stimulation adjustments. Over six decades, SCS has evolved from an experimental modality rooted in theoretical neurophysiology into a sophisticated, programmable, and increasingly personalized neuromodulation therapy. Mechanisms of Action and Rationale for Neuromodulation What Is SCS’s mechanism? It modulates pain pathways effectively and safely. The mechanisms underlying spinal cord stimulation (SCS) are multifaceted, involving segmental, spinal, and supraspinal modulation of pathological nociceptive processing. Classical tonic SCS was initially grounded in the gate control theory, which proposed that activation of large-diameter Aβ fibers in the dorsal columns inhibits transmission from nociceptive C and Aδ afferents through interneuronal gating in the dorsal horn (Melzack & Wall 1965). Contemporary neurophysiological studies have confirmed that dorsal column activation increases GABAergic inhibitory signaling, reduces glutamatergic excitation, suppresses dorsal horn hyperexcitability, and decreases wide dynamic range neuron firing key contributors to neuropathic pain sensitization (Heijmans 2020). What Is SCS’s impact on the nervous system? It alters pain processing at multiple levels. Beyond segmental mechanisms, SCS also modulates descending inhibitory pathways arising from brainstem nuclei, and alters thalamocortical and limbic network activity involved in the sensory-discriminative and affective dimensions of pain. Functional imaging shows decreased cortical activity in regions responsible for salience and emotional amplification, providing a rationale for improved pain coping and reduced catastrophizing with effective neuromodulation (Caylor 2019). Modern stimulation paradigms expand this mechanistic framework. High-frequency stimulation (>1 kHz) produces analgesia without generating action potentials or paresthesias, likely through desynchronization of pathological firing and subthreshold membrane modulation. Burst stimulation delivers temporally patterned pulses that preferentially influence medial pain pathways and limbic circuits, targeting the emotional–motivational aspects of pain (Chakravarthy 2019). What Is SCS in modern therapy? It’s essential for treating certain chronic pain conditions. Closed-loop SCS introduces a transformational mechanistic advance. By measuring evoked compound action potentials (ECAPs), the system directly quantifies spinal cord activation and adjusts stimulation output to maintain consistent neural recruitment. This physiologic “dose control” reduces periods of overstimulation and understimulation and stabilizes therapeutic efficacy across posture and movement (Levy 2019, Levy 2024). Together, these mechanisms demonstrate that SCS is not merely a gating therapy but a sophisticated neuromodulatory intervention capable of recalibrating abnormal pain networks at multiple levels of the neuraxis. What Is SCS’s broader application? It is not limited to pain management but also aids rehabilitation. Indications Spinal cord stimulation (SCS) is indicated for chronic pain conditions in which neuropathic or mixed neuropathic mechanisms dominate and where symptoms persist despite guideline-directed medical therapy, rehabilitation, and appropriate interventional approaches.

Failed Back Surgery Syndrome – Persistent Spinal Pain

Failed Back Surgery Syndrome – Persistent Spinal Pain Persistent Spinal Pain Syndrome Type 2 (PSPS-T2), formerly termed Failed Back Surgery Syndrome (FBSS), describes chronic low-back and/or radicular pain that persists or recurs after one or more spinal operations. The underlying pathophysiology is multifactorial and may involve postoperative nerve root injury, epidural fibrosis, and recurrent foraminal or central stenosis. Other factors include facet degeneration, discogenic pathology, or segmental instability. Central sensitization mechanisms can perpetuate Persistent Spinal Pain (Nissen et al., 2018; Palmer et al., 2019). Understanding Persistent Spinal Pain and Its Treatment Options Spinal Cord Stimulation (SCS) has become one of the most advanced and effective treatment options for patients who continue to experience significant back or leg pain after one or more spine surgeries—a condition now termed Persistent Spinal Pain Syndrome Type 2 (PSPS-T2). Many individuals with this condition have already tried medications, physical therapy, and injections, or even additional surgeries, yet their pain persists. Persistent Spinal Pain is a debilitating condition that affects many individuals, often leading to significant lifestyle changes. In PSPS-T2, a major component of the pain is often neuropathic, described as burning, electric, sharp, or shooting. This type of pain typically responds poorly to standard medications (Palmer et al., 2019). SCS delivers controlled electrical pulses to the spinal cord to reduce these abnormal pain signals before they reach the brain. The scientific evidence supporting SCS is strong. One of the key randomized controlled studies showed that patients receiving SCS experienced significantly greater pain reduction, improved physical function, and higher satisfaction. They also had reduced reliance on medications compared with those treated with medical therapy alone (Kumar et al., 2007). Modern technological advancements have further expanded the benefits of SCS. High-frequency stimulation at 10 kHz, for example, provides consistent relief for both back and leg pain without producing tingling sensations, which some patients find uncomfortable (Kapural et al., 2015). This newer approach has allowed SCS to help a broader range of PSPS-T2 patients, including those with severe axial low-back pain. Long-term studies also show durable outcomes. In real-world follow-up, most patients who benefit from SCS during the initial trial continue to experience meaningful relief for many years after implantation (Nissen et al., 2018). Finally, comprehensive comparative research including a 2025 network meta-analysis evaluating all major treatments for PSPS-T2 found neuromodulation therapies like SCS to provide the most effective overall pain reduction and improvements in daily functioning (Goudman et al., 2025). Managing Persistent Spinal Pain effectively requires a comprehensive understanding of the various treatment modalities available. For patients whose pain persists despite conventional treatments, SCS offers a scientifically validated, reversible, and highly targeted solution designed to restore comfort, mobility, and quality of life. SCS Procedure & Targets in Failed Back Surgery Syndrome / Persistent Spinal Pain Persistent Spinal Pain can often lead to a decreased quality of life, making effective treatments essential. Spinal Cord Stimulation (SCS) is a minimally invasive neuromodulation therapy designed to directly address chronic back and leg pain in patients with Failed Back Surgery Syndrome / Persistent Spinal Pain Syndrome Type 2 (PSPS-T2). Patients dealing with Persistent Spinal Pain may find relief through various treatment options tailored to their specific needs. Step 1: The Trial Procedure The process begins with a temporary trial—an essential step that allows patients to experience the therapy before committing to a permanent implant. The physician places thin, flexible leads through a needle into the epidural space, without the need for open surgery. These leads connect to an external pulse generator worn on a belt or clothing. Over the next 3–7 days, patients test whether stimulation meaningfully reduces their pain or improves daily functioning. A successful trial typically means at least 50% pain reduction, improved sleep, better mobility, or a decrease in medication use. Long-term studies show that patients who respond well during the trial are highly likely to maintain meaningful benefit after permanent implantation (Nissen et al., 2018). Step 2: Permanent Implantation If the trial is successful, a permanent system is implanted. The leads are placed in the same epidural location but secured more firmly. A small implantable pulse generator (IPG) is positioned under the skin, usually in the upper buttock or lower abdomen. Understanding the nuances of Persistent Spinal Pain is crucial for patients considering their treatment options. Modern rechargeable IPGs last many years and support advanced waveforms such as 10 kHz high-frequency stimulation, which does not produce paresthesia (Kapural et al., 2015). The entire procedure typically takes under an hour, and most patients return home the same day. Target Locations: Tailored to the Pain Pattern Precise targeting is key to the success of SCS. The placement of leads is customized based on the dominant pain type: Radicular leg or sciatic pain: Leads are placed around the mid-thoracic spine (T8–T10), corresponding to lumbar and sacral dermatomes. This placement is well established in major clinical studies (Kumar et al., 2007). Central or axial low-back pain: Traditional low-frequency stimulation is often less effective for midline back pain. Modern high-frequency (10 kHz) and burst stimulation have shown superior coverage of deep dorsal horn circuits, providing robust relief without paresthesia (Kapural et al., 2015; Palmer et al., 2019). Persistent Spinal Pain can be challenging to manage, but innovative therapies continue to emerge. Why These Targets Work In PSPS-T2, ongoing pain may come from nerve root irritation, postoperative scarring, altered spinal biomechanics, and central sensitization. SCS aims to normalize these dysregulated pathways. By placing leads directly over the segments transmitting pain signals, stimulation effectively “rebalances” how the spinal cord processes pain. Clinical Outcomes & Long-Term Efficacy of SCS in Failed Back Surgery Syndrome / Persistent Spinal Pain Spinal Cord Stimulation (SCS) is one of the most extensively studied advanced treatments for patients with Failed Back Surgery Syndrome / Persistent Spinal Pain Syndrome Type 2 (PSPS-T2). These patients frequently continue to experience severe neuropathic leg pain, axial back pain, or combined pain patterns despite surgery, medications, physical therapy, and injections. Across multiple randomized trials, cohort studies, and systematic reviews, SCS consistently demonstrates meaningful and

Spinal Cord Stimulation (SCS) and Complex Regional Pain Syndrome

Complex Regional Pain Syndrome Complex Regional Pain Syndrome (CRPS) is a chronic, progressive neuropathic pain disorder characterized by continuous regional pain that is disproportionate to the inciting event, accompanied by sensory, vasomotor, sudomotor, and motor–trophic abnormalities. The condition typically develops after trauma, surgery, or immobilization, though the severity of symptoms often exceeds the magnitude of the original injury. CRPS is broadly classified into CRPS-I, occurring without confirmed nerve injury, and CRPS-II, which follows an identifiable nerve lesion. Its diagnosis is clinical and based on the internationally accepted Budapest Criteria, requiring a combination of symptoms and physical signs across four domains and the exclusion of alternative explanations (Mattie et al., 2024). The pathophysiology of CRPS is multifactorial and remains incompletely understood. Proposed mechanisms include neurogenic inflammation, nociceptive sensitization, sympathetic dysregulation, microvascular dysfunction, and maladaptive neuroplasticity, all of which interact to sustain pain and autonomic changes long after tissue healing (Mattie et al., 2024). The syndrome imposes a substantial burden on patients due to severe pain, functional decline, and progressive disability. Long-term observational studies demonstrate persistent impairment, with many individuals experiencing limited quality of life even years after onset (Kemler et al., 2008). Management begins with physical and occupational therapy, pharmacologic treatments, and interventional approaches such as sympathetic blocks. In refractory cases, spinal cord stimulation (SCS) has shown the ability to reduce pain and improve quality of life, particularly in early CRPS-I, although its long-term efficacy may diminish in some patients (Kemler et al., 2008). Overall, CRPS represents a complex neuroimmune condition requiring early recognition and multidisciplinary, personalized management to prevent chronic disability. Why SCS for Complex Regional Pain Syndrome Understanding Complex Regional Pain Syndrome Spinal cord stimulation (SCS) is considered one of the most effective interventional therapies for patients with refractory Complex Regional Pain Syndrome (CRPS), primarily because it directly targets the maladaptive neurophysiological processes underlying the disorder. CRPS frequently persists despite comprehensive conservative management including physical therapy, pharmacologic agents, and sympathetic interventions, leaving many patients with disabling neuropathic pain, sensory abnormalities, and functional decline. In such cases, SCS offers a mechanism-based neuromodulatory approach capable of modifying pain processing at the spinal and supraspinal levels (Mattie et al., 2024). SCS works by delivering controlled electrical stimulation to the dorsal columns, engaging large-diameter afferent fibers that inhibit nociceptive transmission and reduce hyperexcitability in dorsal horn neurons. Beyond the classical gate-control explanation, evidence suggests broader effects on descending inhibitory pathways, cortical reorganization, and autonomic dysregulation mechanisms highly relevant to CRPS pathophysiology (Forouzanfar et al., 2004). This makes SCS uniquely positioned to address central sensitization and chronic neuroinflammation that perpetuate CRPS symptoms. Clinical evidence strongly supports the superiority of SCS over conventional therapy alone in the early stages following implantation. Randomized controlled data demonstrate significantly greater pain relief, functional improvement, and patient satisfaction when SCS is combined with standard care compared to rehabilitation alone (Kemler et al., 2008). Medium-term results indicate sustained reductions in pain intensity and improvements in health status across both cervical and lumbar CRPS presentations, reinforcing its applicability across different anatomical distributions (Forouzanfar et al., 2004). Long-term observational analyses show that although analgesic effects may diminish in a subset of patients, most continue to use their device for many years, indicating meaningful functional benefit and high treatment satisfaction (Hoikkanen et al., 2021). Additionally, advancements in stimulation parameters including burst, high-frequency, and waveform-personalized programming provide expanded therapeutic flexibility and may improve clinical responsiveness in selected patients (Ho et al., 2022). Overall, SCS is chosen for CRPS because it provides mechanistically targeted analgesia, clinically significant functional improvement, and durable patient-perceived benefit, making it a critical intervention for individuals who do not respond adequately to conservative treatments. SCS Procedure & Targets in Complex Regional Pain Syndrome Spinal cord stimulation (SCS) is a well-established neuromodulation therapy for patients with refractory Complex Regional Pain Syndrome (CRPS), particularly those who exhibit inadequate response to physical therapy, pharmacologic agents, and interventional sympathectomy. The primary therapeutic rationale for SCS lies in its ability to modulate pathological nociceptive processing within the dorsal columns and associated supraspinal circuits. By delivering controlled electrical impulses to the spinal cord, SCS aims to attenuate central sensitization, restore inhibitory control, and recalibrate maladaptive neuroplastic changes that characterize chronic CRPS (Mattie et al., 2024). The implantation process begins with a trial stimulation phase, an essential predictor of long-term success. Under fluoroscopic guidance, percutaneous epidural leads are introduced into the epidural space and advanced to the rostrocaudal level corresponding to the patient’s painful region. For patients with upper-extremity CRPS, leads are typically positioned over the cervical dorsal columns (C5–T1), whereas lower-extremity CRPS commonly requires lead placement at the mid-to-lower thoracic segments (T8–T12). During the 5–7 day trial, clinicians evaluate pain reduction, paresthesia coverage, functional improvements, and patient satisfaction. Successful trials often defined as ≥50% pain reduction or significant improvement in daily functioning lead to permanent implantation of the internal pulse generator (IPG) (Kemler et al., 2008). The mechanism of action is historically grounded in Melzack and Wall’s Gate Control Theory, where activation of large-diameter Aβ fibers electrically overrides the transmission of nociceptive input. However, contemporary research suggests a multifaceted effect involving dorsal horn interneuron recruitment, descending modulatory pathway enhancement, anti-inflammatory signaling, and cortical reorganization critical factors in the pathophysiology of CRPS (Forouzanfar et al., 2004). Advancements in SCS technology have expanded therapeutic possibilities beyond conventional tonic stimulation. Patients may benefit from burst stimulation, high-frequency (10 kHz) paradigms, or multiplexed waveforms that provide paresthesia-free analgesia, reduced accommodation, and enhanced patient comfort. Randomized controlled trials comparing different stimulation parameters demonstrate that waveform personalization may improve clinical outcomes, although tonic low-frequency SCS continues to serve as the foundation of CRPS neuromodulation (Ho et al., 2022). Despite procedural challenges including lead migration, hardware malfunctions, and occasional infections SCS remains one of the most effective interventional treatments for CRPS. When applied early in the disease course and supported by multidisciplinary rehabilitation, SCS offers sustained pain relief, improved quality of life, and functional recovery for appropriately selected patients. Clinical Outcomes & Long-Term Efficacy of SCS in Complex Regional Pain Syndrome Spinal cord

Spinal Cord Stimulation (SCS) and Peripheral Neuropathic Pain

SCS and Peripheral Neuropathic Pain Peripheral Neuropathic Pain: Definition, Mechanisms, and Clinical Spectrum Peripheral neuropathic pain (PNP) is defined as pain arising from a lesion or disease affecting the peripheral somatosensory system. It represents a highly heterogeneous clinical entity encompassing metabolic, ischemic, infectious, traumatic, toxic, compressive, and postoperative nerve injuries. Regardless of etiology, patients frequently experience spontaneous burning pain, electric-shock sensations, paresthesias, allodynia, and hyperalgesia, often accompanied by sleep disturbance, emotional distress, and functional impairment (Wolter, 2014; Burkey et al., 2023). Traditional pharmacologic therapy provides clinically meaningful benefit in only a minority of individuals, underscoring the substantial unmet need in this patient population. Metabolic and microvascular forms include painful diabetic neuropathy, one of the most common and debilitating neuropathic syndromes, characterized by distal symmetric sensory loss and severe burning pain resulting from chronic hyperglycemic and ischemic injury to small and large fibers (Yeung et al., 2024; Henson et al., 2021). Ischemic neuropathic pain, often associated with critical limb ischemia or diabetic foot disease, develops when chronic hypoperfusion induces neural degeneration, ulceration, and tissue breakdown—frequently culminating in high amputation risk (Zhang et al., 2025). Infectious causes include postherpetic neuralgia, a classic neuropathic condition driven by varicella-zoster–related ganglionic and peripheral nerve injury, especially prevalent in older adults and often refractory to first-line medications (Li et al., 2025). Traumatic and post-surgical neuropathic pain syndromes arise after direct peripheral nerve damage or excessive surgical traction. Entrapment neuropathies, such as those involving the peroneal or tibial nerves, further contribute to the clinical spectrum. Additionally, toxic neuropathies from chemotherapeutic agents or environmental exposures, as well as idiopathic small-fiber neuropathies, remain important contributors to chronic pain burden. Several reviews highlight that these diverse entities share overlapping mechanisms, including ectopic discharges, ion channel dysregulation, maladaptive plasticity, and microvascular compromise (Dones & Levi, 2018; Burkey et al., 2023). Given this broad etiologic landscape and the limited effectiveness of pharmacotherapy, interest has increasingly shifted toward neuromodulatory treatments such as spinal cord stimulation, which demonstrate promising results across multiple neuropathic pain subtypes. Why SCS for Peripheral Neuropathic Pain Spinal cord stimulation (SCS) has emerged as a leading interventional therapy for peripheral neuropathic pain (PNP) because it directly targets the dysfunctional neural circuits underpinning chronic pain. Whereas conventional pharmacologic treatments often provide incomplete or transient relief—benefiting fewer than half of patients—SCS modulates aberrant dorsal horn and supraspinal processing, offering more consistent and durable analgesia across a wide range of neuropathic conditions (Wolter, 2014; Burkey et al., 2023). Its mechanisms extend beyond classical gate control, involving modulation of wide dynamic range neuron hyperexcitability, suppression of ectopic discharges, restoration of inhibitory interneuronal balance, and improved microcirculatory function in ischemic tissues (Dones & Levi, 2018). Importantly, SCS demonstrates efficacy across multiple PNP etiologies. In painful diabetic neuropathy, high-quality evidence shows substantial and sustained reductions in pain intensity alongside improvements in sensory deficits and sleep quality (Yeung et al., 2024; Henson et al., 2021). In ischemic neuropathic pain associated with diabetic foot or critical limb ischemia, SCS enhances microvascular perfusion, reduces tissue ischemia, and may delay or reduce amputation risk—benefits not achievable with medication alone (Zhang et al., 2025). For postherpetic neuralgia, SCS attenuates persistent central sensitization and has shown clinically meaningful improvements even in elderly patients with long-standing symptoms (Li et al., 2025). Beyond analgesia, SCS provides functional and quality-of-life improvements that pharmacologic therapies rarely achieve. Studies consistently demonstrate enhanced mobility, reduced sleep disturbance, improved mood, and decreased reliance on analgesic medications, including opioids. Its minimally invasive, reversible nature and capacity for individualized programming further contribute to its appeal as a long-term therapeutic strategy. Collectively, these factors position SCS as one of the most evidence-supported neuromodulatory options for patients with refractory peripheral neuropathic pain across diverse etiologies. SCS Procedure & Targets in Peripheral Neuropathic Pain The Impact of SCS and Peripheral Neuropathic Pain Understanding SCS and Peripheral Neuropathic Pain The procedural framework of spinal cord stimulation (SCS) for peripheral neuropathic pain (PNP) integrates careful patient selection, precise lead placement, and tailored programming strategies to modulate pathologic neural activity. SCS is performed in two stages: a temporary trial phase, typically lasting 3–10 days, followed by permanent implantation in responders who achieve at least 50% pain reduction or meaningful functional improvement. This staged approach allows individualized assessment of expected benefit and reduces unnecessary implantation (Wolter, 2014; Burkey et al., 2023). Lead placement is guided by dermatomal mapping and pain distribution. For lower-limb neuropathic pain including diabetic neuropathy, ischemic pain, traumatic mononeuropathies, and radiculopathic components leads are generally positioned in the epidural space between T8 and T12, targeting dorsal column fibers that innervate the lower extremities (Yeung et al., 2024). Upper-limb neuropathic syndromes, although less common in the included literature set, are typically addressed with leads placed between C4 and T2. Paresthesia-based systems require precise overlap between stimulation-induced sensations and painful regions, whereas paresthesia-free paradigms (burst or high-frequency stimulation) enable broader and more flexible targeting without sensation dependence (Dones & Levi, 2018). Target selection also reflects the underlying neuropathic mechanism. In painful diabetic neuropathy, stimulation of the dorsal columns modulates hyperexcitable nociceptive pathways and improves microcirculatory dynamics, contributing to both analgesia and sensory recovery (Henson et al., 2021). In ischemic neuropathic pain, SCS increases peripheral perfusion through sympathetic inhibition and improved vasomotion, offering a dual effect on pain and tissue viability (Zhang et al., 2025). For postherpetic neuralgia, lead placement commonly centers around the thoracic segments corresponding to affected dermatomes; modulation of central sensitization and inhibition of hyperactive dorsal horn neurons are key mechanisms (Li et al., 2025). Programming parameters including pulse width, amplitude, and frequency are iteratively optimized to achieve maximal analgesia with minimal adverse effects. Modern devices support multiple waveforms, allowing clinicians to switch between tonic, burst, and high-frequency modes depending on patient response and tolerability (Burkey et al., 2023). Throughout the process, multidisciplinary follow-up ensures proper wound healing, device integration, and long-term management of neuropathic symptoms. Overall, SCS procedural strategy and segmental targeting are central to achieving successful outcomes across diverse peripheral neuropathic pain subtypes. These components ensure precise modulation of pathological circuits while